A meta-analysis of five case-control studies found serum alpha-tocopherol levels roughly 1.17 standard deviations lower in people with MS compared to healthy controls, but evidence remains limited by small sample sizes and substantial heterogeneity. Further prospective research is needed before drawing firm conclusions about causation or therapeutic implications.
Oxidative stress is implicated in MS pathology, and alpha-tocopherol, the active form of vitamin E, functions as a primary chain-breaking antioxidant in the body. This systematic review and meta-analysis pooled data from five case-control studies comprising 389 total participants: 211 with MS and 178 healthy controls. The researchers searched four major databases (Scopus, PubMed, Web of Science, Embase) through March 2025 and applied rigorous inclusion criteria and bias assessment using Joanna Briggs Institute tools.
The quantitative synthesis revealed that serum alpha-tocopherol concentrations were significantly lower in the MS group compared to controls (standardized mean difference = -1.17; 95% confidence interval: -2.02 to -0.31; p = 0.007). This represents a clinically meaningful difference in circulating levels of this antioxidant nutrient. However, the heterogeneity between studies was substantial (I2 = 91.5%), meaning the individual studies varied considerably in their findings. The predictive interval spanned from -3.13 to 0.79, illustrating considerable uncertainty around where future study results might fall.
The authors conducted subgroup analyses stratified by sample size, sex, and disease phase to explore the source of heterogeneity, but these analyses did not identify clear explanations for the variability between studies. This unresolved heterogeneity is an important limitation: it suggests that study design differences, population characteristics, measurement methods, or other unmeasured factors may be driving divergent results. The retrospective nature of all included case-control studies also limits causal inference. Association is not causation, and case-control designs cannot establish whether lower alpha-tocopherol precedes MS onset or results from the disease process itself.
The authors explicitly acknowledge these constraints and recommend that future research employ multicenter, prospective study designs with larger sample sizes. Such designs would allow researchers to determine whether baseline alpha-tocopherol status predicts MS development and whether restoring levels provides any clinical benefit.
This finding is descriptive rather than actionable in its current form. The association between lower serum alpha-tocopherol and MS presence is statistically supported by the pooled data, but several factors prevent immediate clinical translation:
On supplementation: The evidence does not yet support alpha-tocopherol supplementation as a therapeutic strategy for MS. The studies measured serum levels in people with existing disease; they did not test whether supplementing with vitamin E alters disease course, relapse rates, or progression. Case-control comparisons cannot answer whether raising alpha-tocopherol would be beneficial. Clinical trials specifically testing supplementation would be required.
On dietary sources: Vitamin E-rich foods (nuts, seeds, vegetable oils, leafy greens) are nutritionally sound as part of a balanced diet, but no evidence presented here specifically links dietary vitamin E intake to MS outcomes. The mechanism by which oxidative stress contributes to MS pathology is still being elucidated, and antioxidants have shown mixed results in MS research overall.
For people with MS: If you have MS, discuss any supplement decisions with your neurologist. Some antioxidant interventions have been explored in MS, but individual tolerability and interactions with disease-modifying therapies vary. This single meta-analysis should not redirect medical management.
| Characteristic | Detail |
|---|---|
| Study type | Systematic review and meta-analysis |
| Studies included | 5 case-control studies |
| Total participants | 389 (211 MS, 178 controls) |
| Primary measure | Serum alpha-tocopherol concentration |
| Main finding | SMD = -1.17 (95% CI: -2.02, -0.31); p = 0.007 |
| Heterogeneity | I2 = 91.5% (substantial) |
| Journal | BioMed Research International |
| Published | 2025 |
| PubMed ID | 42421296 |
| Risk of bias assessment | Joanna Briggs Institute critical appraisal tool |
| Limitations noted | Small number of included studies, retrospective designs, unresolved heterogeneity, case-control design cannot establish causation |
Primary source:
Association Between Serum Alpha-Tocopherol and Pathogenesis of Multiple Sclerosis: A Systematic Review and Meta-Analysis of Case-Control Studies - BioMed Research International, 2025. PubMed.
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.